Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study Of LMB-9, A Recombinant Disulfide Stabilized Anti-Lewis Y Immonutoxin Administered By 5-Days Continuous Infusion For Patients With Colorectal Adenocarcinoma

NCT00010270 is registered in ClinicalTrials.gov with University Hospital Freiburg as lead sponsor.

NCT NCT00010270
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00010270 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study Of LMB-9, A Recombinant Disulfide Stabilized Anti-Lewis Y Immonutoxin Administered By 5-Days Continuous Infusion For Patients With Colorectal Adenocarcinoma
Lead sponsor
University Hospital Freiburg
Phase
Phase 1
Overall status
Unknown status
Start date
April 30, 2001
Completion date
Not reported
Enrollment
50 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer, esophageal cancer, gastric cancer, pancreatic cancer